Linkoping

• A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc … Unknown
  2022-502779-40-99 5 Primary prevention of atherosclerotic cardiovascular disease (ASCVD)
• IntReALL BCP 2020 – International Study for Treatment of Childhood Relapsed Precursor B-cell ALL 2020 Pending
  2023-509392-17-00 5 Relapsed Acute Lymphoblastic Leukemia (ALL)
• GLUTAMICS III Pending
  2024-513575-40-01 5 Acute kidney injury and heart failure after coronary artery bypass sur
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• ALASCCA-A randomized double-blind placebo-controlled study with ASA treatment in colorectal cancer patients with mutations in the PI3K signa … Pending
  2024-513778-23-00 5 Colon and rectal cancer tumor stage II-III, tumor with somatic alterat
• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke … Pending
  2024-514682-19-00 5 Resected pancreatic ductal adenocarcinoma
• The Swedish Nationwide Clinical Trial to Facilitate Patient Access to Targeted Cancer Treatment based on Biomarker Profiling (FOCU.SE) Pending
  2024-516003-16-00 4 Advanced Cancer
• SGLT2 inhibitor or metformin as standard treatment in early type 2 diabetes (SMARTEST) Pending
  2024-516228-33-00 6 Type 2 Diabetes
• A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent O … Pending
  2024-516327-14-00 4 Ovarian cancer
• A multicenter, randomized, open-label, blinded-assessor, phase 4 study in patients with early rheumatoid arthritis to compare active convent … Pending
  2024-516723-14-00 6 Rheumatoid Arthritis
• A randomised, prospective phase II study of pharmacokinetics and safety aspects of higher doses of rifampicin and pyrazinamide in a shortene … Pending
  2024-518772-32-00 4 Tuberculosis
• An interventional, Open-label Study to Evaluate the effect of lebrikizumab on eczema and Skin Barrier Function parameters in lesional and no … Pending
  2024-519811-32-00 6 Atopic dermatitis
• Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year Pending
  2025-521590-13-00 5 Moderately to Severely Active Crohn’s Disease
• Contrast Strategy In Fenestrated EndoVascular Aneurysm Repair Randomized Control Trial Pending
  2025-521795-58-00 11 Abdominal aortic aneurysm
• Randomized Open Label Trial Evaluating Efficacy and Safety of Intravenous Immunoglobulin (IVIg, Privigen) as Add-on to SoC Versus SoC Alone … Pending
  2025-522756-97-00 4 COVID-19 and Severely Impaired B-cell Function
• PODOMOUNT-Basket, a study to test whether BI 764198 helps adults and adolescents with different types of kidney disease Pending
  2025-523425-17-00 4 Proteinuric kidney diseases
• Tick-Borne Encephalitis (TBE) Remdesivir Efficacy Assessment Trial (TREAT) Pending
  2025-523476-23-00 4 Tick-Borne Encephalitis (TBE)
• Patient Evaluation of OraFID, a New Medicine Dispenser and App for Flexilev minitablets Pending
  2025-524296-23-01 6 Parkinsons Disease
• A clinical study of sacituzumab tirumotecan in people with ovarian cancer (MK-2870-021) Recruiting
  2023-508047-40-00 5 2026-04-30 Ovarian cancer
• AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer (TREVI-OC-01) Recruiting
  2025-520466-22-00 5 2026-04-29 Advanced Platinum-resistant Epithelial Ovarian Cancer
• A study to find out if BI 764198 helps adults and adolescents with a kidney condition called focal segmental glomerulosclerosis (FSGS) Recruiting
  2025-522191-86-00 5 2026-04-02 Focal segmental glomerulosclerosis
• A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting
  2025-521514-26-00 5 2026-01-26 Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer W
• PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting
  2024-512922-27-00 4 2025-11-25 Mantle Cell Lymphoma (MCL)
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P

Showing 1–24 of 172 trials